Kourzeq Oral Paste launched for Canker Sore and oral inflammatory lesions

A distinctive feature of KOURZEQ is its exclusive availability through telehealth services, made possible through a strategic partnership between MidAmerica Pharmaceuticals and BeyondMD®. Interested consumers can visit kourzeq.doctalkgo.com to set up a virtual consultation with a qualified healthcare professional. If deemed appropriate following the assessment, the prescription for KOURZEQ can be ordered and delivered directly to the patient's doorstep.

Eve del Rio, MD, Chief Medical Officer for MidAmerica Pharmaceuticals, expressed the company's commitment to providing a swift and effective remedy for canker sores. "We are pleased to be offering a new FDA-approved option for those living with, and suffering from, canker sores. We are confident that KOURZEQ will make a positive difference for those suffering from canker sores."

Linda Brennan, the MidAmerica Pharmaceuticals CEO added saying "After seeing firsthand how painful canker sores can be, I created MidAmerica Pharmaceuticals so that we can bring a solution to millions of people."

The telehealth distribution model aims to streamline the process of obtaining both expert healthcare advice and access to KOURZEQ. John Bernard, M.D., Medical Director for BeyondMD, emphasized the relief this will bring to canker sore sufferers.

Source:

Pharmaceuticals, M. (2023, November 14). MidAmerica Pharmaceuticals Launches KOURZEQTM Oral Paste - an FDA Approved Prescription Medication that Helps Canker Sores Heal Faster. MidAmerica Pharmaceuticals.